Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

Opening
Remarks

Paul Villanti, Executive Director Programs, Movember Christoper Sweeney, ICECaP Principal Investigator, Medical Oncology, Dana-Farber Cancer Institute

ICECaP Adjuvant Presentations

Health Economics Presentations

Harmonization Presentations

STOPCAP Presentations

ICECaP Biology Presentations

ICECaP Adjuvant Presentations

ICECaP Updates

Chris Sweeney

ICECaP Principal Investigator,
Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Update on data collection for ICECaP2

Praful Ravi

Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Example of assessing new PSA based endpoints

Wanling Xie

Biostatistics,
Dana-Farber Cancer Institute.

View Presentation

Health Economics Presentations

Progress on creating a health economics model in adjuvant prostate cancer setting

Richard De Abreu Lourenco

Health Economics,
University of Technology Sydney

View Presentation

Discuss goal to credential QALY gained from preventing a PSA relapse as an endpoint

Chris Sweeney

ICECaP Principal Investigator,
Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Harmonization Presentations

Progress of writing a guidance document for conduct of adjuvant trials

Anis Hamid
Medical Oncology, University of Melbourne

View Presentation

STOPCAP Presentations

Progress on IPD data collection and network meta-analyses for treatment effects

Jayne Tierney

Evidence Synthesis
University College London

View Presentation

Progress on prognostic models and surrogacy

Susan Halabi

Biostatistics and Bioinformatics, Duke University

View Presentation

Proposal of simple prognostic model

Chris Sweeney

Medical Oncology
Dana-Farber Cancer Institute

View Presentation

ICECaP Biology Presentations

Progress: prelim data, sample collection, and plans:

M1HSPC: STAMPEDE-ADT, doc, abi; CHAARTED; ENZAMET, PEACE-1
Adjuvant: STAMPEDE-ADT, doc, abi; NRG; ENZARAD

Gerhardt Attard
Medical Oncology, University College London

View Presentation

Copyright © 2021 Movember. All rights reserved.
Movember Foundation is a registered 501(c)3 non-profit organization.